The study of population pharmacokinetics (PPK) and individualized dosage of lobaplatin regimens in olderly patients with small cell lung cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-15006057

Enrollment

Unknown

Registered

2015-03-04

Start date

2014-06-25

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small lung cancer

Interventions

small lung cancer :chemotherapy regimens Lobaplatin-contained

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Not less than 65 years old,male or female patients; 2.With the diagnosis of Small cell lung cancer confirmed by pathological or cytology tests; 3.Without limiting the phase and the once treatment; 4.With measurable tumor foci(According to RECIST v1.1); 5.ECOG PS: 0-2; 6.Life expectancy >=3 months; 7.Laboratory parameters: Bone marrow function: ANC>=1.5*10^9/L; PLT>=100*10^9/L; HB>=90g/L; Hepatic function: STB and CB=60 ml/min (Cockcroft-Gault); Coagulation function:PT INR<=ULN*1.5; 8.Voluntary to participate and sign informed consent document.

Exclusion criteria

Exclusion criteria: 1.Allergic to platinum drugs used in the past; 2.The patients with coagulation dysfunction; 3.Other patients that are not suitable for inclusion;

Design outcomes

Primary

Measure	Time frame
Blood and Plasma concentration of lobaplatin at each time point;	—

Secondary

Measure	Time frame
the Safety;the effectiveness;	—

Countries

China

Contacts

Public ContactYing Cheng

chengying@csco.org.cn+86 0431-85871236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026